3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
23
INDUSTRY
13
NIH
4
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, B-Cell
1
Interventions
Radiotherapy, Intensity-Modulated
3
Cisplatin
3
pembrolizumab
2
Metformin
2
Laparoscopy
2
Gemcitabine
2
Capecitabine
2
tremelimumab
1
sintilimab
1
nabiximols
1
lenvatinib
1
enzalutamide
1
durvalumab
1
capivasertib
1
avelumab
1
atezolizumab
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
abiraterone
1
Zoledronic Acid
1
Trastuzumab
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Rituximab
1
Rehabilitation
1
Radiotherapy, Conformal
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Radiation
1
Rabeprazole
1
Proton Pump Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
OTHER_GOV
×
avelumab
×
Clear all
NCT03244176
2024-07-30
AvR-CHOP
Austin Health
Phase EARLY_PHASE1
Active not recruiting
28 enrolled